PMID- 32974362
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 7
DP  - 2020
TI  - Evaluation of UroVysion for Urachal Carcinoma Detection.
PG  - 437
LID - 10.3389/fmed.2020.00437 [doi]
LID - 437
AB  - Background: Patients with hematuria who are positive for urinary fluorescence in 
      situ hybridization (FISH) are generally considered to have urothelial carcinoma. 
      We determined whether UroVysion FISH could be used for the diagnosis of urachal 
      carcinoma. Methods: Seven cases of urachal carcinoma with haematuria subjected to 
      FISH analysis were retrospectively analyzed in our hospital from May 2012 to 
      November 2019. Paraffin-embedded tissue sections from one FISH-positive and one 
      FISH-negative urachal carcinoma were processed in strict accordance with the 
      instructions of the UroVysion kit. Meanwhile, FISH data from the other 414 
      hematuria patients were collected as controls. Results: All 7 patients with 
      urachal carcinoma were diagnosed with adenocarcinoma. According to Sheldon stage, 
      six patients had stage IIIa and one patient had stage IVb. The sensitivity and 
      specificity of urinary FISH for the diagnosis of urachal carcinoma were 71.43% 
      (5/7) and 94.61% (281/297), respectively. The rates of polysomy for chromosomes 3 
      and 7 in positive patients were both 100% (5/5), whereas the rate of polysomy for 
      chromosome 17 was 40% (2/5), and the chromosome 9p21 region (p16) gene deletion 
      rate was 20% (1/5). Histological assessment and cytological FISH were consistent 
      for urachal carcinoma. No significant difference was observed in the diagnostic 
      efficacy between urachal carcinoma and urothelial carcinoma (71.43 vs. 87.18%, P 
      = 0.245). Conclusions: Taken together, UroVysion FISH was found to be positive in 
      a high proportion of pathologically confirmed urachal carcinoma of late stage 
      with hematuria. Its chromosomal aberrations may be different from those of 
      urothelial carcinoma, but more studies are needed to clarify their genetic 
      background. Not all tumors showing abnormalities by FISH are urothelial 
      carcinomas.
CI  - Copyright (c) 2020 Hu, Ke, Liu, Zeng, Li, Xu and Yang.
FAU - Hu, Zhiquan
AU  - Hu Z
AD  - Department of Urology, Tongji Hospital Affiliated to Tongji Medical College of 
      Huazhong University of Science and Technology (HUST), Wuhan, China.
FAU - Ke, Chunjin
AU  - Ke C
AD  - Department of Urology, Tongji Hospital Affiliated to Tongji Medical College of 
      Huazhong University of Science and Technology (HUST), Wuhan, China.
FAU - Liu, Zheng
AU  - Liu Z
AD  - Department of Urology, Tongji Hospital Affiliated to Tongji Medical College of 
      Huazhong University of Science and Technology (HUST), Wuhan, China.
FAU - Zeng, Xing
AU  - Zeng X
AD  - Department of Urology, Tongji Hospital Affiliated to Tongji Medical College of 
      Huazhong University of Science and Technology (HUST), Wuhan, China.
FAU - Li, Song
AU  - Li S
AD  - Department of Urology, Tongji Hospital Affiliated to Tongji Medical College of 
      Huazhong University of Science and Technology (HUST), Wuhan, China.
FAU - Xu, Hua
AU  - Xu H
AD  - Department of Urology, Tongji Hospital Affiliated to Tongji Medical College of 
      Huazhong University of Science and Technology (HUST), Wuhan, China.
FAU - Yang, Chunguang
AU  - Yang C
AD  - Department of Urology, Tongji Hospital Affiliated to Tongji Medical College of 
      Huazhong University of Science and Technology (HUST), Wuhan, China.
LA  - eng
PT  - Journal Article
DEP - 20200827
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC7482390
OTO - NOTNLM
OT  - UroVysion
OT  - differential diagnosis
OT  - fluorescence in situ hybridization
OT  - urachal carcinoma
OT  - urothelial carcinoma
EDAT- 2020/09/26 06:00
MHDA- 2020/09/26 06:01
PMCR- 2020/08/27
CRDT- 2020/09/25 06:04
PHST- 2020/05/11 00:00 [received]
PHST- 2020/07/06 00:00 [accepted]
PHST- 2020/09/25 06:04 [entrez]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2020/09/26 06:01 [medline]
PHST- 2020/08/27 00:00 [pmc-release]
AID - 10.3389/fmed.2020.00437 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2020 Aug 27;7:437. doi: 10.3389/fmed.2020.00437. 
      eCollection 2020.